Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Cy5 Goat Anti-Mouse IgG: Assay Design
2026-09-11
The Cy5 Goat Anti-Mouse IgG (H+L) Antibody provides a versatile fluorescent readout for mouse primary antibodies. This article explains how to deploy it as an analytical layer in osteogenesis and exosome studies, with emphasis on controls, interpretation, and workflow design.
-
Dicloxacillin Activity Inside and Outside S. aureus
2026-09-11
Sandberg et al. combined a THP-1 intracellular model with a murine peritonitis model to compare dicloxacillin activity against Staphylococcus aureus in intracellular and extracellular compartments. The study showed that free-drug time above the MIC was the most informative PK/PD index in both settings, while differences in sampling time and dosing schedule explained important model discordance.
-
Cell lysis buffer for WB and IP: Lab Guide
2026-09-10
Learn how Cell lysis buffer for WB and IP, SKU K1123, can stabilize protein workflows that follow viability, proliferation, and cytotoxicity assays. This scenario-based guide connects inhibitor-supported, non-denaturing extraction with Western blotting, immunoprecipitation, and tumor-microenvironment research while distinguishing product capabilities from study-specific evidence.
-
Minocycline HCl for EV Inflammation Workflows
2026-09-10
Use Minocycline HCl as a controlled perturbation in extracellular-vesicle, inflammation, and neuroprotection experiments—not merely as an antibiotic. This workflow pairs fresh solution handling, EV-specific controls, and scalable iMSC-EV production concepts to separate drug effects from vesicle-mediated biology.
-
Chronic Cabozantinib Signaling Adaptation in RCC
2026-09-09
This 2026 study uses quantitative phosphoproteomics to distinguish acute from chronic Cabozantinib adaptation in renal cell carcinoma cells. It identifies persistent suppression of activating MET phosphorylation alongside selective adhesion-, stress-, and MAPK/AP-1-associated remodeling, with context-dependent changes in migration and invasion.
-
Bovine Insulin: Cell Culture Mechanisms & Workflow
2026-09-09
Bovine insulin is a double-chain peptide hormone used as a metabolic and trophic supplement in cell culture. Its insulin receptor signaling pathway can support glucose metabolism regulation and cell growth, but product solubility, vehicle controls, and model-specific validation determine experimental reliability.
-
Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells
2026-09-08
The reference study identifies a phenotypic small-molecule screening strategy for reducing SPP1 expression in tumor-associated macrophages and integrates promising hits into a TAM-avid CANDI nanoformulation. Its lead compound, CANDI460, reduced SPP1 in vitro and in vivo and produced tumor remissions in multiple murine models, offering a framework for tumor microenvironment macrophage modulation.
-
Reserpine (N1867) Lab Workflow Guide
2026-09-08
Reserpine (SKU N1867) is a high-purity research compound for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide covers identity checks, DMSO preparation, storage, and assay QC; the material is for research use only and is not intended for diagnostic, therapeutic, veterinary, or clinical applications.
-
Firefly Luciferase mRNA: A Delivery-Aware Reporter
2026-09-07
Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) provides a sensitive way to separate delivery, translation, and biological response in reporter experiments. This article connects its molecular design with recent gastrointestinal mRNA-LNP delivery research and practical assay decisions.
-
Firefly Luciferase mRNA: Workflow & Troubleshooting
2026-09-07
Firefly Luciferase mRNA provides a fast, non-integrating control for transfection, expression, viability, and imaging workflows. Its ARCA cap, 5mCTP, pseudouridine, and optimized poly(A) tail support consistent reporter production while making delivery and assay variables easier to diagnose.
-
Crizotinib hydrochloride: Assay Reliability Guide
2026-09-05
This scenario-based guide explains how Crizotinib hydrochloride (SKU B3608) can improve interpretation of viability, proliferation, and cytotoxicity assays in ALK-, c-Met-, or ROS1-relevant cancer models. It connects kinase-phosphorylation measurements, patient-derived assembloids, formulation handling, and vendor-selection criteria to practical laboratory decisions.
-
Exosomal SNORD52 Activates JAK2/STAT6 in HCC
2026-09-04
A 2025 Discover Oncology study identifies hepatoma cell-derived exosomal SNORD52 as an intercellular regulator of M2 macrophage polarization in hepatocellular carcinoma. By combining exosome analysis, THP-1 macrophage experiments, qRT-PCR, western blotting, and flow cytometry, the work connects a non-coding RNA cargo to JAK2/STAT6 pathway activation and tumor-microenvironment remodeling.
-
Catalpol, Glycolysis, and EphA2/FAK/Src in Liver Fibrosis
2026-09-04
A 2024 Phytomedicine study identifies inhibition of aerobic glycolysis in hepatic stellate cells as a key component of catalpol’s antifibrotic activity. The work connects catalpol target engagement at EphA2 with reduced EphA2–FAK association and suppression of downstream FAK/Src signaling, providing a mechanistic framework for evaluating metabolic control of liver fibrosis.
-
Chronic Cabozantinib Phosphoproteomics in RCC
2026-09-03
This 2026 study uses quantitative phosphoproteomics to distinguish acute from chronic Cabozantinib adaptation in renal cell carcinoma cells. Its main contribution is showing that long-term exposure preserves MET activation-loop suppression while selectively reshaping adhesion-, stress-, and MAPK/AP-1-associated phosphorylation programs linked to modest, context-dependent motility changes.
-
Optimized hiPSC Platelet Differentiation: Key Findings
2026-09-03
Yue et al. developed an optimized differentiation scheme that increases megakaryocyte and platelet production from human induced pluripotent stem cells while shortening culture time and reducing cost. The study combines higher embryoid body input, human platelet lysate, cytokine-replacing small molecules, and maturation-promoting compounds to generate functional platelets with measurable clot-forming activity.